Reputation and power: Organizational image and pharmaceutical regulation at the FDA

Reputation and Power: Organizational Image and Pharmaceutical Regulation at the FDA

Volumn , Issue , 2014, Pages 1-802

  Carpenter, Daniel ^a  

^a HARVARD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84924759316     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Book

References (474)

1. Louis Galambos and Jeffrey Sturchio, "Pharmaceutical Firms and the Transition to Biotechnology: A Study in Strategic Innovation," Business History Review 72 (2) (Summer 1998): 256-60;.
2. Walter W. Powell, "The Social Construction of an Organizational Field: The Case of Biotechnology," International Journal of Biotechnology 1 (1) (1999): 42-67.
3. Robert Teitelman, Gene Dreams: Wall Street, Academia, and the Rise of Biotechnology (New York: Basic Books, 1989).
4. Maggie Mahar, "The Genentech Mystique: How Much Science? How Much Hype?" Barron's (Jan. 11, 1988).
5. Baruch A. Brody, Ethical Issues in Drug Testing, Approval and Pricing: The Clot-Dissolving Drugs (New York: Oxford University Press, 1995);.
6. Charles Mather, Usher Fleising, and Liam Taylor, "Translating Knowledge from Bench to Bedside: The Controversial Social Life of t-PA," Risk Management: An International Journal 6 (2) (2004): 49-60.
7. Toshihiro Nishiguchi (Managing Product Development (New York: Oxford University Press, 1996), 240-55).
8. Philip Hilts (Protecting America's Health: The FDA, Business, and One Hundred Years of Regulation (New York: Knopf, 2003, 300-303) also offer able and engaging summaries of the scientific (and political) issues at stake.
9. Stephen Skowronek, Building a New American State: The Construction of National Administrative Capacities, 1877-1920 (New York: Cambridge University Press, 1982), chapters 1-5;.
10. Daniel Carpenter, The Forging of Bureaucratic Autonomy: Reputations, Networks and Policy Innovation in Executive Agencies, 1862-1928 (Princeton: Princeton University Press, 2001), introduction, chap. 2, and chap. 10.
11. Jack Citrin, "Comment: The Political Relevance of Trust in Government," APSR 68(3) (Sept. 1974): 973-88;.
12. Joseph S. Nye, Philip D. Zelikow, and David C. King, Why People Don't Trust Government (Cambridge: Harvard University Press, 1997).
13. Steven Van de Walle and Geert Bouckaert, "Public Service Performance and Trust in Government: The Problem of Causality," International Journal of Public Administration 26(8, 9) (Jan. 2003): 891-913.
14. Kessler recounts the episode in his book, A Question of Intent: A Great American Battle with a Deadly Industry (New York: Public Affairs Press, 2002);.
15. Allan Brandt, The Cigarette Century: the Rise, Fall and Deadly Persistence of the Product that Defined America (New York: Basic Books, 2007), 391-97.
16. Hawthorne, Inside the FDA, 58-60.
17. Martha Derthick, Up in Smoke: From Legislation to Litigation in Tobacco Politics, 2nd ed. (Washington, DC: Congressional Quarterly Press, 2004), chapters 1, 4, and 8.
18. Paul Pierson, Dismantling the Welfare State? Reagan, Thatcher and the Politics of Retrenchment (Cambridge: Cambridge University Press, 1994);.
19. Jacob Hacker, The Divided Welfare State (New York: Cambridge University Press, 2002);.
20. Monica Prasad, The Politics of Free Markets: The Rise of Neoliberal Economic Policies in Britain, France, Germany and the United States (Chicago: University of Chicago Press, 2006).
21. Edwin Amenta, Bold Relief: Institutional Politics and the Origins of Modern American Social Policy (Princeton: Princeton University Press, 1998);.
22. Jennifer Klein, For All These Rights: Business, Labor, and the Shaping of America's Public-Private Welfare State (Princeton: Princeton University Press, 2004).
23. Ellis Hawley, The New Deal and the Problem of Monopoly (Princeton: Princeton University Press, 1966).
24. On transportation regulation, consult Ari Hoogenboom and Olive Hoogenboom, A History of the ICC: From Panacea to Palliative (New York: Norton, 1976);.
25. Lawrence Rothenberg, Regulation, Organizations and Politics: Motor Freight Policy at the Interstate Commerce Commission (Ann Arbor: University of Michigan Press, 1994).
26. Brandice Canes-Wrone, "The Influence of Congress and the Courts over the Bureaucracy: An Analysis of Wetlands Policy," in Scott Adler and John Lapinski, eds., The Macropolitics of Congress (Princeton: Princeton University Press, 2006).
27. James L. Baughman, Television's Guardians: The FCC and the Politics of Programming, 1958-1967 (Knoxville: University of Tennessee Press, 1985);.
28. Barry Cole and Mal Oettinger, The Reluctant Regulator: The FCC and the Broadcast Audience (Boston: Addison Wesley, 1978).
29. Shalini Venturelli, Liberalizing the European Media: Politics, Regulation and the Public Sphere (Oxford: Oxford University Press, 1998).
30. Peter Temin, Taking Your Medicine: Drug Regulation in the United States (Cambridge: Harvard University Press, 1980);.
31. Marcia Angell, The Truth About the Drug Companies: How They Deceive Us and What To Do About It (New York: Random House, 2004);.
32. Richard Epstein, Overdose: How Excessive Government Regulation Stifles Pharmaceutical Product Innovation (New Haven: Yale University Press, 2007).
33. Harry M. Marks, "Revisiting the Origins of Compulsory Drug Prescriptions," American Journal of Public Health 85 (1) (1995): 109-15;.
34. The Progress of Experiment (New York: Cambridge University Press, 1997).
35. Aseem Prakash and Matthew Potoski, The Voluntary Environmentalists: Green Clubs, ISO 14001, and Voluntary Environmental Regulations (New York: Cambridge University Press, 2006);.
36. Cary Coglianese and Jennifer Nash, Regulating from the Inside (Washington, DC: Resources for the Future, 2001).
37. Joseph V. Rees, Reforming the Workplace: A Study of Self-Regulation in Occupational Safety (Philadelphia: University of Pennsylvania Press, 1998).
38. Stephen Skowronek, Building a New American State: The Expansion of National Administrative Capacities, 1877-1920 (New York: Cambridge University Press, 1982);.
39. Thomas K. McCraw, Prophets of Regulation (Cambridge: Harvard Belknap, 1984);.
40. Morton Keller, Regulating a New Economy: Public Policy and Economic Change in America, 1900-1933 (Cambridge: Harvard University Press, 1990);.
41. Elizabeth Sanders, Roots of Reform: Farmers, Workers, and the American State, 1877-1917 (Chicago: University of Chicago Press, 1999);.
42. William Novak, The People's Welfare: Law and Regulation in Nineteenth-Century America (Chapel Hill: University of North Carolina Press, 1999);.
43. Scott C. James, Presidents, Parties and the State: A Party-System Perspective on Democratic Regulatory Choice, 1877-1935 (New York: Cambridge University Press, 2000).
44. Paul L. Joskow and Roger G. Noll, "Regulation in Theory and Practice: An Overview," in Gary Fromm, ed., Studies in Public Regulation (Cambridge: MIT Press, 1981).
45. Cass R. Sunstein, After the Rights Revolution: Reconceiving the Regulatory State (Cambridge:Harvard University Press, 1990);.
46. Stephen G. Breyer, Breaking the Vicious Cycle: Toward Effective Risk Regulation (Cambridge: Harvard University Press, 1993);.
47. W. Kip Viscusi, Fatal Tradeoffs: Public and Private Responsibilities for Risk (New York: Oxford University Press, 1992).
48. William Gormley, Jr., "A Test of the Revolving Door Hypothesis at the FCC," American Journal of Political Science 23 (4) (Nov. 1979): 665-83.
49. Sam Peltzman, "Toward a More General Theory of Regulation," Journal of Law and Economics 19 (Aug. 1976): 211-40.
50. Gary S. Becker, "A Theory of Competition Among Pressure Groups for Political Influence," Quarterly Journal of Economics 98 (Aug. 1983): 371-400.
51. Arthur Denzau and Michael Munger, "Legislators and Interest Groups: How Unorganized Interests Get Represented," APSR 80 (1986), 89-106.
52. Joseph P. Kalt and Mark A. Zupan, "Capture and Ideology in the Economic Theory of Politics," American Economic Review 74 (June 1984): 279-300.
53. Spiller, "Politicians, Interest Groups and Regulators: A Multiple-Principals Agency Theory of Regulation, Or, 'Let Them Be Bribed,'" Journal of Law and Economics 22 (April 1990): 65-101.
54. Gene Grossman and Elhanan Helpman, Special Interest Politics (Cambridge: MIT Press, 2001).
55. Kelman, Regulating America, Regulating Sweden (Cambridge, MIT Press, 1981) (occupational safety and health);.
56. Balogh, Chain Reaction (New York: Cambridge University Press, 1993) (commercial nuclear power);.
57. Mashaw and Harfst, The Struggle for Auto Safety (Cambridge, MA: Harvard University Press, 1990) (automobile safety regulation);.
58. Carpenter, The Forging of Bureaucratic Autonomy: Networks, Reputations and Policy Innovation in Executive Agencies, 1862-1928 (Princeton: Princeton University Press, 2001) (food and drug regulation, national forest management).
59. Barry R. Weingast, "The Congressional-Bureaucratic System," in Institutions of American Democracy: The Executive Branch (New York:Oxford University Press, 2005).
60. John D. Huber and Nolan M. McCarty, "Bureaucratic Capacity, Delegation, and Political Reform," APSR 98(3) (2004): 481-94.
61. Erving Goffman, The Presentation of the Self in Everyday Life (New York: Doubleday, 1959).
62. Other treatments include Goffman's Interaction Ritual: Essays on Face-to-Face Behavior (New York: Pantheon, 1967).
63. Stigma:Notes on the Management of Spoiled Identity (New York: Simon & Schuster, 1963).
64. John F. Padgett and Christopher K. Ansell, "Robust Action and the Rise of the Medici, 1400-1434," American Journal of Sociology (1993): 1259-1319.
65. Jay A. Clarke, Becoming Edvard Munch: Influence, Anxiety, and Myth (New Haven: Yale University Press, 2009), esp. pp. 61-108;.
66. Kevin Sharpe, Selling the Tudor Monarchy: Authority and Image in Sixteenth-Century England (New Haven: Yale University Press, 2009).
67. Henri Tajfel and John C. Turner, "An Integrative Theory of Intergroup Conflict," in W. G. Austin and S. Worchel, eds., The Social Psychology of Intergroup Relations (Monterey: Brooks-Cole, 1979);.
68. Duncan Watts, "Identity and Search in Social Networks," Science 296 (2002): 1302-5.
69. David Kreps, "Corporate Culture and Economic Theory," in James Alt and Kenneth Shepsle, eds., Rational Perspectives on Political Science (New York: Cambridge University Press, 1986).
70. Tom R. Tyler, "Psychological Perspectives on Legitimacy and Legitimation," Annual Review of Psychology 57 (2006): 375-400;.
71. J. T. Jost and B. Major, The Psychology of Legitimacy: Emerging Perspectives on Ideology, Justice and Intergroup Relations (New York: Cambridge University Press, 2001).
72. Keith Whittington, Political Foundations of Judicial Supremacy (Princeton: Princeton University Press, 2007), esp. chapters 3 and 5;.
73. James L. Gibson and Gregory A. Caldeira, "Defenders of Democracy? Legitimacy, Popular Acceptance, and the South African Constitutional Court," Journal of Politics 65 (2003): 1-30;.
74. Gibson, Caldeira, and Virginia A. Baird, "On the Legitimacy of High Courts," APSR 92 (1998): 343-58.
75. John R. Hibbing and Elizabeth Theiss-Morse, Stealth Democracy: Americans' Beliefs About How Government Should Work (New York: Cambridge University Press, 2002);.
76. Joseph S. Nye, Philip D. Zelikow, and David C. King, Why People Don't Trust Government (Cambridge:Harvard University Press, 1998).
77. James Clifford, The Predicament of Culture: Twentieth-Century Ethnography, Literature and Art (Cambridge:Harvard University Press, 1988), 344.
78. Ann Swidler, Talk of Love: How Culture Matters (Chicago: University of Chicago Press, 2001);.
79. Nina Eliasoph and Paul Lichterman, "Culture in Interaction," American Journal of Sociology 108 (4) (Jan. 2003): 735-94;.
80. Harrison White, Identity and Control: A Structural Theory of Social Action (Princeton: Princeton University Press, 1992).
81. John Kingdon, Agendas, Alternatives and Public Policies (Boston: Little, Brown, 1984);.
82. Frank Baumgartner and Bryan Jones, Agendas and Instability in American Politics (Chicago:University of Chicago Press, 1993);.
83. Jones and Baumgartner, The Politics of Attention: How Government Prioritizes Problems.
84. John I. Kitsuse and Malcolm Spector, "Toward a Sociology of Social Problems: Social Conditions, Value Judgments, and Social Problems," Social Problems 20 (1973): 407-18;.
85. Stephen Hilgartner and Charles L. Bosk, "The Rise and Fall of Social Problems: A Public Arenas Model," American Journal of Sociology 94 (1988): 53-78.
86. Michael E. Levine and Jennifer L. Forrence, "Regulatory Capture, Public Interest, and the Public Agenda: Toward a Synthesis," Journal of Law, Economics and Organization 6 (Special Issue): 167-98.
87. Kingdon, Agendas, Alternatives and Public Policies;.
88. Deborah Stone, "Causal Stories and the Formation of Policy Agendas," Political Science Quarterly 104(2) (Summer 1989): 281-300.
89. Keith Krehbiel, Information and Legislative Organization (Ann Arbor: University of Michigan Press, 1991);.
90. Kathleen Bawn, "Political Control Versus Expertise: Congressional Choices about Administrative Procedures," APSR 89 (1995): 62-73;.
91. David Epstein and Sharyn O'Halloran, Delegating Powers: A Transaction-Cost Perspective on Policy Making Under Separate Powers (New York: Cambridge University Press, 1999).
92. Jonathan Bendor and Adam Meirowitz ("Spatial Models of Delegation," APSR 98 (2) (2004): 293-310), who show that risk-aversion is not necessary for many important results in this literature.
93. David E. Lewis, "The Politics of Agency Termination: Confronting the Myth of Immortality," Journal of Politics 64 (1) (2002): 89-107;.
94. Carpenter and Lewis, "Political Learning from Rare Events: Poisson Inference, Fiscal Constraints, and the Lifetime of Bureaus," Political Analysis 12 (3) (2004): 201-32.
95. Donald J. Pisani, Water and American Government: The Reclamation Bureau, National Water Policy, and the West, 1902-1935 (Berkeley: University of California Press, 2002);.
96. Carpenter, The Forging of Bureaucratic Autonomy, chap. 10.
97. Jason A. MacDonald and William W. Franko, Jr., "Bureaucratic Capacity and Bureaucratic Discretion: Does Congress Tie Policy Authority to Performance?" American Politics Research 35 (2007): 790-807.
98. Balogh, Chain Reaction;.
99. Carpenter, The Forging of Bureaucratic Autonomy;.
100. J. Charles Schencking, Making Waves: Politics, Propaganda, and the Emergence of the Imperial Japanese Navy, 1868-1922 (Stanford: Stanford University Press, 2005).
101. Christopher Foreman, Signals from the Hill: Congressional Oversight and the Challenge of Social Regulation (New Haven: Yale University Press, 1988);.
102. Herbert Kaufman, The Administrative Behavior of Federal Bureau Chiefs (Washington, DC: Brookings Institution, 1981).
103. A. K. Weyman, N. F. Pidgeon, J. Walls, and T. Horlick-Jones, "Exploring Comparative Ratings and Constituent Facets of Public Trust in Risk Regulatory Bodies and Related Stakeholder Groups," Journal of Risk Research 9 (2006): 605-22;.
104. Paul Slovic, "Perceived Risk, Trust and Democracy," Risk Analysis 13 (1993): 675-82;.
105. M. P. White and J. R. Eiser, "Information Specificity and Hazard Risk Potential as Moderators of Trust Asymmetry," Risk Analysis 25 (2005): 1187-98.
106. Peter Swenson, Capitalists Against Markets: The Making of Labor Markets and Welfare States in the United States and Sweden (New York: Oxford University Press, 2002).
107. Charles O. Jackson, Food and Drug Legislation in the New Deal (Princeton: Princeton University Press, 1970).
108. James Harvey Young, The Medical Messiahs: A Social History of Health Quackery in Twentieth-Century America (Princeton: Princeton University Press, 1967).
109. Harry M. Marks, "Revisiting 'The Origins of Compulsory Drug Prescriptions,'" American Journal of Public Health 85 (1) (Jan. 1995): 109-15;.
110. Peter Temin, Taking Your Medicine: Drug Regulation in the United States (Cambridge: Harvard University Press, 1980);.
111. Paul M. Wax, "Elixirs, Diluents, and the Passage of the 1938 Federal Food, Drug and Cosmetic Act," AnnIM 122 (6) (March 15, 1995): 456-61.
112. Ramunas A. Kondratas, "Biologics Control Act of 1902," in James Harvey Young, ed., The Early Years of Federal Food and Drug Control (Madison, WI: American Institute for the History of Pharmacy, 1982).
113. Christoph Gradmann, "Redemption, Danger and Risk:The History of Anti-Bacterial Chemotherapy and the Transformation of Tuberculin," in U. Trohler and T. Schlich, eds., The Risks of Medical Innovation: Risk Perception and Assessment in Historical Context (New York: Routledge, 2006), 53-70.
114. Oscar E. Anderson, Jr., The Health of a Nation, Harvey W. Wiley and the Fight for Pure Food (Chicago: University of Chicago Press, 1958);.
115. James Harvey Young, Pure Food (Princeton: Princeton University Press, 1990);.
116. Daniel Carpenter, The Forging of Bureaucratic Autonomy: Reputations, Networks and Policy Innovation in Executive Agencies, 1862-1928, chap. 8.
117. Gustavus Weber, The Food, Drug and Insecticide Administration: Its History, Activities, and Organization (Baltimore: Johns Hopkins University Press, 1928);.
118. Marc T. Law, "How Do Regulators Regulate? Enforcement of the Pure Food and Drugs Act, 1907-1938," Journal of Law, Economics and Organization 22 (2) (2006): 459-89;.
119. Wiley, History of a Crime Against the Food Law (Washington, DC: Harvey W. Wiley, 1929).
120. Young, The Toadstool Millionaires (Princeton: Princeton University Press, 1961).
121. Young, Medical Messiahs, chap. 2.
122. Jackson, Food and Drug Legislation in the New Deal, 96.
123. Jishnu Das, "Do Patients Learn About Doctor Quality? Theory and Evidence from India," Ph.D. diss., Department of Economics, Harvard University (2001);.
124. Daniel Carpenter, "A Simple Theory of Placebo Learning with Self-Remitting Diseases," manuscript, Department of Government, Harvard University, 2005.
125. R. Barker Bausell, Snake-Oil Science: The Truth About Complementary and Alternative Medicine (New York:Oxford University Press, 2007).
126. Guenter B. Risse, Ronald L. Numbers, and Judith Walzer Leavitt, Medicine without Doctors:Home Health Care in American History (New York: Science History Publications, 1977).
127. Alex Berman and Michael A. Flannery, America's Botanico-Medical Movements: Vox Populi (New York: Pharmaceutical Products Press, 2001).
128. Jackson, Food and Drug Legislation in the New Deal, 79, 114.
129. Jackson, Food and Drug Legislation in the New Deal, 63-65, 84, 118.
130. Ruth Deforest Lamb, American Chamber of Horrors: The Truth About Food and Drugs (New York: Farrar & Rinehart, 1935).
131. Gwen Kay, "Healthy Public Relations: The FDA's 1930s Legislative Campaign," Bulletin of the History of Medicine 75 (2001): 446-87.
132. Skocpol, Protecting Soldiers and Mothers (Cambridge: Harvard University Press, 1992);.
133. Clemens, The People's Lobby (Chicago: University of Chicago Press, 1998);.
134. Carpenter, The Forging of Bureaucratic Autonomy, chap. 8.
135. Jackson, Food and Drug Legislation in the New Deal, 38-39.
136. Marks, The Progress of Experiment, 76.
137. "Drug Law Revision Held Over Until Next Session," OP&DR, August 19, 1937.
138. James T. Patterson, Congressional Conservatism and the New Deal (Lexington: University of Kentucky Press, 1967);.
139. Eric Schickler, Disjointed Pluralism (Princeton: Princeton University Press, 2001).
140. David Vogel, Fluctuating Fortunes: The Political Power of Business in America (New York: Basic Books, 1989);.
141. Daniel Carpenter, "Protection without Capture: Product Approval by a Politically Responsive, Learning Regulator," APSR 98 (4) (Nov. 2004): 613-31.
142. John E. Lesch, The First Miracle Drugs: How the Sulfa Drugs Transformed Medicine (New York: Oxford University Press, 2007).
143. Iago Galdston, Behind the Sulfa Drugs: A Short History of Chemotherapy (New York: D. Appleton-Century, 1943).
144. Hilts, Protecting America's Health: The FDA, Business and One Hundred Years of Regulation (New York: Knopf, 2003), 163.
145. Swann, "Sure Cure: Public Policy on Drug Efficacy before 1962," in Gregory J. Higby and Elaine C. Stroud, eds., The Inside Story of Medicines: A Symposium (Madison, WI: American Institute for the History of Pharmacy, 1997), 223-62;.
146. Marks, The Progress of Experiment (New York: Cambridge University Press, 1996), 78-97.
147. Brian Balogh, Chain Reaction: Expert Debate and Public Participation in American Commercial Nuclear Power, 1945-1975 (New York: Cambridge University Press, 1993).
148. Forged Consensus:Science, Technology, and Economic Policy in the United States, 1921-1953 (Princeton:Princeton University Press, 1998).
149. Jessica Wang, American Science in an Age of Anxiety: Scientists, Anticommunism, and the Cold War (Chapel Hill: University of North Carolina Press, 1999);.
150. Don K. Price, Government and Science: Their Dynamic Relation in American Democracy (New York: NYU Press, 1954);.
151. Bruce L. R. Smith, U. S. Science Policy Since World War II (Washington, DC: Brookings Institution, 1990);.
152. Daniel J. Kevles, "The National Science Foundation and the Debate over Postwar Research Policy, 1942-1955," Isis 68 (241) (1977): 4-26;.
153. David Guston and Kenneth Keniston, eds., The Fragile Contract: University Science and the Federal Government (Cambridge: MIT Press, 1994).
154. L. Kay, "Life as Technology: Representing, Intervening and Molecularizing," Rivista di Storia della Scienza, series II, 1 (1993): 85-103.
155. Soraya de Chadarevian and Harmke Kamminga, Molecularizing Biology and Medicine: New Practices and Alliances, 1910s-1970s (Amsterdam: Harwood Academic Publishers, 1998).
156. John P. Swann, Academic Scientists and the U.S. Pharmaceutical Industry:Cooperative Research in Twentieth-Century America (Baltimore: Johns Hopkins University Press, 1988).
157. Jonathan Liebenau, Medical Science and Medical Industry: The Formation of the American Pharmaceutical Industry (London: Macmillan, 1987).
158. Temin, Taking Your Medicine, chap. 4;.
159. Alfred Chandler, Shaping the Industrial Century: The Remarkable Story of the Evolution of the Modern Chemical and Pharmaceutical Industries (Cambridge:Harvard University Press, 2005).
160. Thomas C. Chalmers, "Medical Intelligence: Clinical Pharmacology as an Academic Discipline," NEJM 270 (3) (Jan. 16, 1964): 140-41.
161. A. Bradford Hill, "The Clinical Trial," British Medical Bulletin 7 (1951): 278-82;.
162. Hill, "The Clinical Trial," NEJM 247 (July 24, 1952):113-19;.
163. Hill, Controlled Clinical Trials, Conference of Council for International Organizations of Medical Sciences (Oxford: Blackwell Scientific Publications, 1960).
164. H. Gold, "The Proper Study of Mankind is Man," American Journal of Medicine 12 (1952): 619-20.
165. Kenneth L. Melmon and Howard F. Morelli, Clinical Pharmacology: Basic Principles in Therapeutics, 2nd ed. (New York: Macmillan, 1978), 7-17.
166. K. K. Chen, The American Society for Pharmacology and Experimental Therapeutics-The First Sixty Years, 1908-1969 (New York: ASPET, 1969).
167. Dominique Tobbell, "Pharmaceutical Networks: The Political Economy of Drug Development in the United States, 1945-1980," Ph.D. diss., University of Pennsylvania, 2008.
168. Philip R. Lee and Jessica Herzstein, "International Drug Regulation," Annual Review of Public Health 7 (1986): 218-19.
169. Charles Wesley Dunn, The Food and Drug Law in the United States (Chicago: Commerce Clearing House, 1955).
170. Bernard L. Oser, "The Scientists' Forum," FDCLJ 13 (1958): 192-205.
171. Jeremy A. Greene, "Releasing the Flood Waters: Diuril and the Reshaping of Hypertension," Bulletin of the History of Medicine 79 (4) (2005): 749-97.
172. B. Arret, M. R. Woodard, D. M. Wintermere, and A. Kirshbaum, "Antibiotic Interference Thresholds of Microbial Arrays," Antibiotics and Chemotherapy 12 (10) (Oct. 1957): 545-8.
173. D. C. Grove and W. A. Randall, Assay Methods of Antibiotics: A Laboratory Manual (New York: Medical Encyclopedia, 1955).
174. Henry Welch, Charles N. Lewis, and Chester S. Keefer, Antibiotic Therapy (Washington, DC: Arundel Press, 1951).
175. James Whorten, "Antibiotic Abandon: The Resurgence of Therapeutic Rationalism," in John Parascandola, ed., The History of Antibiotics: A Symposium (Madison, WI: American Institute of the History of Pharmacy, 1980), 129-130;.
176. Finland, "Clinical Uses of the Presently Available Antibiotics," Antibiotics Annual (1953-1954): 10-26;.
177. Hobart A. Reimann, "The Misuse of Antimicrobics," Medical Clinics of North America 45 (1961): 849-56.
178. Scott H. Podolsky, "The Changing Fate of Pneumonia as a Public Health Concern in 20th-Century America and Beyond," American Journal of Public Health 95 (2005): 2144-54.
179. Bruce F. Andreas, M.D., "On the Alert," Blue Print for Health Series, Blue Cross Digest (Summer 1958), 10-13.
180. "Food and Drug Administration," Atlantic City (NJ) Press, June 4, 1955;.
181. T. R. vanDellen, M.D., "How to Keep Well," Chicago Tribune, June 17, 1958 and September 2, 1959;.
182. "The FDA: Guardian of the Nation's Health," Today's Health (June 1959), 36-43.
183. "Drug and Device Seizures," JAMA 172 (18) (April 30, 1960): 167/2097;.
184. "Quack Devices Seized By Food, Drug Agents," AMA News, June 13, 1960;.
185. "FDA Wins Long Battles; Hoxsey, Tri-Wonda Hit," AMA News, October 3, 1960;.
186. "Sales Stopped by Seizure," JAMA 174 (2) (Sept. 10, 1960): 186;.
187. "Government Wins Battle Against Arthritis Remedy," JAMA 174 (12) (Nov. 19, 1960): 1642;.
188. "Larrick Outlines FDA Activities," JAMA 176 (8) (May 27, 1961): 17.
189. Annabel Hecht, "Hocus-Pocus as Applied to Arthritis," FDA Consumer (Sept. 1980).
190. Cabell Phillips, "U.S. Food-Drug Agency Has Broad Powers," NYT, November 15, 1959.
191. Nate Haseltine, "Tough FDA to Get Tougher in Future," WP, December 26, 1961.
192. "There Ought to Be a Law," Time (July 9, 1956), 60.
193. Taussig, "The Thalidomide Syndrome," Scientific American 207 (2): 29-35.
194. "Take Warning from Thalidomide," New York Herald Tribune, July 31, 1962.
195. Saturday Review, September 1, 1962;.
196. George Gallup, "Mrs. Kennedy Is Most Admired Woman," Washington Post-Tribune Herald, December 26, 1962, B7.
197. "Dr. Kelsey's Stubborn Triumph," Good Housekeeping, November 1962;.
198. "Dr. Kelsey, Heroine," Catholic Standard, August 10, 1962;.
199. "Doctor and the Drug," Newsweek 60 (July 30, 1962): 70;.
200. "Thalidomide Disaster," Time 80 (August 10, 1962): 32;.
201. "Drug Market Guardian:Frances Oldham Kelsey," NYT, August 2, 1962, A1;.
202. J. Mulliken, "Woman Doctor Who Would Not Be Hurried," Life 53 (Aug. 10, 1962): L28-29;.
203. "Inside Story of a Medical Tragedy:Interview," U.S. News 53 (Aug. 13, 1962): 54-55;.
204. D. Wolfle, "Thalidomide Lesson," Science 137 (Aug. 17, 1962): 497;.
205. "Vigilant Doctor Gets a Medal," U.S. News 53 (Aug. 20, 1962): 13;.
206. W. Jonathan, "Feminine Conscience of FDA: Dr. Frances Oldham Kelsey," Saturday Review 45 (Sept. 1, 1962): 41-43;.
207. "Parents Magazine Honors Dr. Frances Oldham Kelsey for Outstanding Service to Family Health," Parents Magazine 37 (Oct. 1962): 64;.
208. Morton Mintz, "Doctor Kelsey Said No," Reader's Digest 81 (Oct. 1962): 86-9;.
209. "Toward Safer Drugs," Consumer Reports 27 (Oct. 1962): 509-11;.
210. Jonathan Lear, "Reward," Saturday Review 46 (Feb. 2, 1963): 47;.
211. "Thalidomide Heroine Seeks New Culprits," Scientific Digest 53 (May 1963): 32;.
212. "Lady Cop," Newsweek 61 (June 24, 1963): 100.
213. Mary Tinley Daly, "Dr. Kelsey, Heroine," Catholic Standard, August 10, 1962, p. 10.
214. Harry Marks, The Progress of Experiment: Science and Therapeutic Reform, 1900-1990 (New York: Cambridge University Press, 1997).
215. Beauchamp, A History and Theory of Informed Consent New York: Oxford University Press, 1986).
216. Carl C. Pfeiffer, "Problems in Drug Development as they Relate to the Clinical Investigator," Journal of New Drugs (Nov.-Dec. 1964): 299-305.
217. Kenneth L. Melmon and Howard F. Morelli, eds., Clinical Pharmacology: Basic Principles in Therapeutics, 2nd ed. (New York: Macmillan, 1978), chap. 1.
218. John Whitehead, The Design and Analysis of Sequential Clinical Trials (Chichester, Horwood, NY: Halsted Press, 1983);.
219. P. C. O'Brien and T. R. Fleming, "A Multiple Testing Procedure for Clinical Trials," Biometrics 35 (1979): 549-56.
220. Whitehead, "Stopping Clinical Trials by Design," NRDD 3 (Nov. 2004): 973-7.
221. Cytel Software Corporation, EaSt: A Software Package for the Design and Interim Monitoring of Group Sequential Clinical Trials (Cambridge, MA: Cytel, 2000);.
222. Mathsoft, Incorporated, S-Plus SeqTrial (Seattle: Mathsoft, 2000);.
223. David Cowen, "Ethical Drugs and Medical Ethics," The Nation 189 (22) (Dec. 26, 1959):479-82;.
224. "The A.M.A. and the U.S.A," Time, July 7, 1961, 56;.
225. Charlotte Muller, "The Overmedicated Society: Forces in the Marketplace for Medical Care," Science 176 (1972): 488-92;.
226. Goddard, "The Drug Establishment," Esquire, March 1969, 120-21;.
227. Mintz, The Therapeutic Nightmare;.
228. Jesse D. Rising, "The Practicing Physician's Approach to the Evaluation of New Drugs," Canadian Medical Association Journal 19 (Nov. 16, 1964): 1046-50.
229. Miriam Ottenberg, "The Story of MER/29-Was the Public Protected?" Washington (Sunday) Star, August 26, 1962.
230. M. Elizabeth Magill, "Agency Choice of Policymaking Form," University of Chicago Law Review 71 (2004): 1383-1447.
231. James J. Kilpatrick, "Uncle Sam Coddles the Consumer," Saturday Evening Post, July 13, 1968.
232. Musser and John O'Neill, Pharmacology and Therapeutics (New York: Macmillan, 1961);.
233. John H. Moxley III, Gary L. Yingling, and Charles C. Edwards, "The Food and Drug Administration's over-the-counter drug review: why review OTC drugs?" Proceedings of the Federation of Independent Scientists 32 (4) (April 1973): 1435-7.
234. Lars Noah, "Treat Yourself:Is Self-Medication the Prescription for What Ails American Health Care?" Harvard Journal of Law and Technology 19 (2) (Spring 2006): 359-92.
235. Thomas W. Merrill and Kathryn Tongue Watts, "Agency Rules with the Force of Law: The Original Convention," Harvard Law Review 116 (2) (Dec. 2002): 467-592.
236. Richard A. Merrill, "Architecture.".
237. Hutt, "Impact of Recent Court Decisions on the Future of FDA Regulations: An Impromptu Response to the Remarks of the Speakers," FDCLJ 28 (1973): 707, 712.
238. The Organizational State (Madison: University of Wisconsin Press, 1987).
239. Paul Starr, The Social Transformation of American Medicine (New York: Basic Books, 1982);.
240. Jacob Hacker, The Divided Welfare State (New York: Cambridge University Press, 2002);.
241. Jonathan Oberlander, The Political Life of Medicare (Chicago:University of Chicago Press, 2003), 21-33, 98;.
242. Theodore R. Marmor, The Politics of Medicare, 2nd ed. (Chicago: Aldine, 2000).
243. Peltzman, "An Evaluation of Consumer Protection Legislation: The 1962 Drug Amendments," Journal of Political Economy 81 (5) (Sept.-Oct. 1973), 1049-91.
244. Peltzman, Regulation of Pharmaceutical Innovation: The 1962 Amendments (Washington, DC: American Enterprise Institute, 1974);.
245. Grabowski, Drug Regulation and Innovation:Empirical Evidence and Policy Options (Washington, DC: American Enterprise Institute, 1976).
246. Grabowski, Vernon, and Lacy Glenn Thomas, "Estimating the Effects of Regulation on Innovation: An International Comparative Analysis of the Pharmaceutical Industry," Journal of Law and Economics 21 (1978): 133-63.
247. Kennedy, "A Calm Look at 'Drug Lag'," JAMA 239 (1978): 423-6;.
248. Wardell, "A Close Inspection of the 'Calm Look': Rhetorical Amblyopia and Selective Amnesia and the Food and Drug Administration," JAMA 239 (1978): 2004-11.
249. Wardell and Lasagna, Regulation and Drug Development, chap. 13;.
250. Yale Brozen, "Foreword" to Grabowski, Drug Regulation and Innovation, 8.
251. Kramer, "The F.D.A.'s Callous Response to AIDS," NYT, March 23, 1987, A19;.
252. "Drugs for the Dying," WP, July 11, 1989, A24.
253. Philip Hilts (Protecting America's Health: The FDA, Business, and One Hundred Years of Regulation (New York: Knopf, 2003), chapters 16 and 17;.
254. Hawthorne, Inside the FDA (New York: Wiley, 2005), chap. 10;.
255. Arthur Daemmrich, Pharmacopolitics: Drug Regulation in the United States and Germany (Chapel Hill: University of North Carolina Press, 2004), chapters 2 and 4;.
256. Ceccoli, Pill Politics: Drugs and the FDA (Boulder, CO: Lynne Rienner, 2004), chap. 5.
257. I. R. Hart and I. J. Fidler, "Role of Organ Selectivity in the Determination of Metastatic Patterns of B16 Melanoma," Cancer Research 40 (1980): 2281-87.
258. Emil Frei III, et al., "The Effectiveness of Combinations of Antileukemic agents in Inducing and Maintaining Remission in Children with Acute Leukemia," Blood 26 (1965): 642-56.
259. J. H. Moxley III, Vincent DeVita, K. Brace, and Emil Frei III, "Intensive Combination Chemotherapy and X-irradiation in Hodgkin's Disease," Cancer Research 27 (1967): 1258-63;.
260. DeVita, A. A. Serpick, and P. P. Carbone, "Combination Chemotherapy in the Treatment of Advanced Hodgkin's Disease," AnnIM 73 (1970): 881-5;.
261. M. Levitt, et al., "Combination Sequential Chemotherapy in Advanced Reticulum Cell Sarcoma," Cancer 29 (1972): 630-36;.
262. D. Berd, J. Cornog, R. C. Conti, M. Levitt, and Joseph Bertino, "Long-term Remission in Diffuse Histiocytic Lymphoma Treated with Combination Sequential Chemotherapy," Cancer 35 (1975): 1050-54;.
263. Gianni Bonadonna, et al., "Combination Chemotherapy as an Adjuvant Treatment in Operable Breast Cancer," NEJM 294 (1976): 405-10.
264. Alberto Cambrosio, Peter Keating, and Andrei Mogoutov, "Protocols, Regimens and Substances: The Socio-Technical Space of Anti-Cancer Drugs," in Jean Paul Gaudillière and Volker Hess, eds., Ways of Regulating: Therapeutic Agents between Plants, Shops, and Consulting Rooms (Preprint 363) (Berlin: Max-Planck-Institut für Wissenschaftsgeschichte, 2009).
265. Zubrod, "The National Program for Cancer Chemotherapy," JAMA 222 (1972): 1161-2;.
266. C. H. Takimoto, "Anticancer Drug Development at the U.S. National Cancer Institute," Cancer Chemotherapy and Pharmacology 52 (2003) (Supplement 1): 29-33;.
267. Lloyd R. Kelland, "Of Mice and Men: Values and Liabilities of the Athymic Nude Mouse Model in Anticancer Drug Development," European Journal of Cancer 40 (2004): 827-36.
268. Rosenberg, L. Van Camp, and T. Krigas, "Inhibition of Cell Division in Escherichia coli by Electrolysis Products from a Platinum Electrode" (letter), Nature 205 (1965): 698-9.
269. Rosenberg, Van Camp, E. B. Grimley, et al., "The Inhibition of Growth or Cell Division in Escherichia coli by Different Ionic Species of Platinum (IV) Complexes," Journal of Biological Chemistry 242 (1967): 1347-52;.
270. Rosenberg, Van Camp, et al., "Platinum Compounds: A New Class of Potent Antitumour Agents" (letter), Nature 222 (1969): 385-6.
271. Rosenberg, "Cisplatin: Its History and Possible Mechanisms of Action," chap. 2.
272. Archie W. Prestayko, Stanley T. Crooke, and Stephen K. Carter, Cisplatin: Current Status and New Developments (New York: Academic Press, 1980);.
273. Jeff Lyon, "Tempo: Winning the War against the Disease Men Fear Most," Chicago Tribune, September 19, 1982, I-1.
274. David M. Rorvik, "Laetrile: The Goddamned-Contraband-Apricot Connection," Newsletter of the Alicia Patterson Foundation (New York: Alicia Patterson Foundation, 1976): MSS 78-7, McNaughton Foundation Papers, UCSF.
275. "NCI Mulls Laetrile Trial," DRR 20 (22) (June 1, 1977);.
276. "NCI Decision on Laetrile Trials Near," DRR 20 (28) (July 13, 1977);.
277. "HEW Launching Study of Cancer Victims Treated Only with Laetrile; Legal Hurdles Seen in Getting Data; Project Less than Popular at NCI," DRR 20 (37) (Sept. 1, 1977): 7.
278. William J. Broad, "New Laetrile Study Leaves Cancer Institute in the Pits," Science 202 (Oct. 6, 1978): 33-36;.
279. "Laetrile Evaluation Underway at NCI," JAMA 239 (1978): 19.
280. B. D. Cohen, "U.S. to Study Laetrile Records," WP, January 27, 1978, A1;.
281. "U.S. Panel's Review of Laetrile Produces Inconclusive Results," WSJ, September 7, 1978, 18;.
282. "U.S. Cancer Institute Seeks Laetrile Tests on Cancer Patients," WSJ, September 28, 1978, 24.
283. "FDA Official Strongly Contends Laetrile Is Ineffective, Subject to U.S. Regulation," WSJ, July 13, 1977, 13;.
284. Lee Edson, "Why Laetrile Won't Go Away," NYT, November 27, 1977.
285. Rosen and Shorr, "Laetrile: End Run Around the FDA," NEJM.
286. Morton Mintz, "Supreme Court Enters Quarrel Over Laetrile," WP, January 23, 1979, A1;.
287. "Justices to Rule Whether the FDA May Bar Use of Laetrile as an Anticancer Drug," WSJ, January 23, 1979, 10;.
288. Morton Mintz, "Justices Voice Skepticism on Laetrile Rulings," WP, April 26, 1979, A14.
289. Smith, Butler, Cohan, and Schein, "Laetrile Toxicity: A Report of Two Patients," Cancer Treatment Reports 62 (1978): 169;.
290. Sadoff, Fuchs, and Hollander, "Rapid Death Associated with Laetrile Ingestion," JAMA 239 (1978): 1532;.
291. Schmidt, "Laetrile Toxicity Studies in Dogs," JAMA 239 (1978): 943.
292. Gail Bronson, "Study Finds Laetrile Can Poison if Taken with Certain Foods," WSJ, March 7, 1978, 35.
293. Townsend and Boni, "Cyanide Poisoning from Ingestion of Apricot Kernels," Morbidity and Mortality Weekly Reports 24 (1975): 427;.
294. "The Case of the Crushed Kernels," Consumer Reports 39 (1974): 514;.
295. Gary Arnold, "Movie Hero Steve McQueen Dies of Heart Attack at Age of 50," WP, November 8, 1980, B4;.
296. "McQueen Death Renews Cancer Treatment Debate," NYT, November 9, 1980, 21.
297. Barron Lerner, "McQueen's Legacy of Laetrile," NYT, November 15, 2005.
298. "Laetrile Tests Show Drug Is Ineffective as Cancer Weapon," WSJ, May 1, 1981, 5;.
299. Victor Cohn, "Laetrile Flunks Test, Is Found As Effective as 'No Treatment'," WP, May 1, 1981, A3.
300. Wallace Janssen, "Cancer Quackery: Past and Present," FDA Consumer (July-August 1977): 27.
301. "New Drug Shows Gain in Fight Against AIDS," NYT, January 26, 1986, A17;.
302. R. Yarchoan, et al., "Administration of 3'-Azido-3'-Deoxythymidine, an Inhibitor of HTLV-III/LAV Replication, to Patients with AIDS or AIDS-Related Complex," Lancet 8481 (March 15, 1986): 575-80;.
303. Jean L. Marx, "AIDS Drug Shows Promise in Preliminary Clinical Trial," Science 231 (March 28, 1986): 1504-5.
304. Erik Eckholm, "AIDS Drug Prolongs Lives in Some Cases," NYT, September 20, 1986, A1;.
305. Erik Eckholm, "Test Group for AIDS Drug Is Broadened to Include 7,000," NYT, October 1, 1986, B6;.
306. Deborah M. Barnes, "Promising Results Halt Trial of Anti-AIDS Drug," Science 234 (Oct. 3, 1986): 15-16.
307. Epstein, Impure Science, 192-3;.
308. Hilts, Protecting America's Health, 243.
309. Philip M. Boffey, "At Fulcrum of Conflict, Regulator of AIDS Drugs," NYT, August 19, 1988, A13.
310. Philip M. Boffey, "Thousands in U.S. Receive Treatments in Experiments," NYT, January 7, 1986, C1;.
311. Proceedings of the Anti-Infective Drugs Advisory Committee, January 16, 1987, 12.
312. Larry Kramer, "The F.D.A.'s Callous Response to AIDS," NYT, March 23, 1987, A19.
313. Philip M. Boffey, "New Initiative to Speed AIDS Drugs Is Assailed," NYT, July 5, 1988, C1.
314. Marilyn Chase, "AIDS Patients Press FDA for New Drugs Due to Rise of Viruses that Resist AZT," WSJ, March 16, 1989, B4;.
315. Robert Reinhold, "Infected but Not Ill, Many Try Unproved Drug to Block AIDS," NYT, May 20, 1987, B12.
316. Epstein, Impure Science, 148-9, 199-200.
317. Boffey, "Campaign to Find Drugs for Fighting AIDS Is Intensified," NYT, February 15, 1988, A1.
318. Gina Kolata, "Despite Promise in AIDS Cases, Drug Faces Testing Hurdle," NYT, December 13, 1988, C3;.
319. Philip M. Boffey, "F.D.A. Is Pessimistic on Drugs to Fight AIDS," NYT, July 14, 1988, B9.
320. Lawrence K. Altman, "F.D.A. Approves First Drug for an AIDS-Related Cancer," NYT, November 22, 1988, C2;.
321. "Five-Minute AIDS Test Is Approved by F.D.A.," NYT, December 14, 1988, A21;.
322. "F.D.A. Acts to Speed Approval of AIDS Drugs," NYT, February 21, 1989, C3.
323. Warren E. Leary, "F.D.A. Approves Drug That Fights Leading Killer of AIDS Patients," NYT, June 16, 1989, D16.
324. Bruce Ingersoll, "FDA to Reconsider Drug for Blindness Connected to AIDS," WSJ, March 3, 1989, B2;.
325. Gina Kolata, "F.D.A. Gives Quick Approval to Two Drugs to Treat AIDS," NYT, June 27, 1989, A1;.
326. Larry Thompson, "Growth Drug Gets FDA Nod," WP, July 4, 1989, H6.
327. Philip J. Hilts, "Side Effects Noted in High Doses of New AIDS Drug," NYT, September 27, 1989, A 20;.
328. Marylyn Chase, "AIDS Drug DDI to be Distributed Widely," WSJ, September 29, 1989, B2;.
329. Hilts, "F.D.A., in Big Shift, Will Permit Use of Experimental AIDS Drug," NYT, September 29, 1989, A1;.
330. Michael Specter, "FDA Authorizes Unproven Drug For AIDS Cases," WP, September 29, 1989, A1.
331. Marilyn Chase, "AZT Expected to Be Cleared for Children," WSJ, October 26, 1989, B2;.
332. "AIDS Drug May Get Wider Use," Chicago Tribune, January 31, 1990, 1-5.
333. Michael Specter, "Pressure from AIDS Activists Has Transformed Drug Testing," WP, July 2, 1989, A1;.
334. Malcolm Gladwell, "Burdened with New Duties, FDA Is Seen Handicapped by Reagan-Era Cuts," WP, September 6, 1989, A21;.
335. Hilts, "How the AIDS Crisis Made Drug Regulators Speed Up," NYT, September 24, 1989, E5;.
336. "A Guardian of U.S. Health Is Failing Under Pressures," NYT, December 4, 1989, A1;.
337. Dick Thompson, "What's the Cure for Burnout?" Time, December 25, 1989, 68.
338. "Foscarnet Approval for Treating CMV Retinitis in AIDS Patients Recommended by FDA Advisory Group," DRR 34 (25) (June 19, 1991): 8.
339. Kramer, The Destiny of Me (New York:Penguin, 1993), 17;.
340. Daemmrich, Pharmacopolitics, 100.
341. John S. James, "ddC: AZT Combination Approval Recommended," AIDS Treatment News, May 1, 1992;.
342. Epstein, Impure Science, 223-4, 267-9.
343. Lawrence K. Altman, "AIDS Study Casts Doubt on Value of Hastened Drug Approval in U.S.," NYT, April 6, 1993, C3.
344. Larry Kramer, "AZT Is Shit," Advocate, May 18, 1993, 80;.
345. Epstein, Impure Science, 304, 430-31.
346. Tim Kingston, "The Coming Storm Over Expedited Drug Approval," San Francisco Bay Times, June 1991, 10-12.
347. Jean-Pierre Aboulker and Ann Marie Swart, "Preliminary Analysis of the Concorde Trial," Lancet 341 (April 3, 1993): 889-90.
348. Epstein, Impure Science, 297-9.
349. Merrill, "The Architecture of Government Regulation of Medical Products," Virginia Law Review 82 (1996): 1768.
350. Crout, "The Nature of Regulatory Choices," FDCLJ 38 (1978): 413.
351. Merrill, "The Architecture of Government Regulation of Medical Products," Virginia Law Review 82 (1996): 1768.
352. David H. Johnson, "Evolution of Cisplatin-Based Chemotherapy in Non-Small Cell Lung Cancer," Chest 117 (4) (April 2000) (supplement): 133S-137S.
353. B. D. Evans, K. S. Raju, A. H. Calvert, S. J. Harland, E. Wiltshaw, "Phase II Study of JM8, a New Platinum Analog, in Advanced Ovarian Carcinoma," Cancer Treatment Reports 67 (1983): 997-1000.
354. GAO, Federal Control of New Drug Testing Is Not Adequately Protecting Human Test Subjects and the Public (Washington, DC, July 15, 1976), HRG-76-96.
355. "GAO Finds Informed Consent Violations Widespread, Most Consent Forms Inadequate," DRR 19 (29), July 21, 1976, 19;.
356. Morton Mintz, "Drug Test Monitoring Called Lax," WP, January 23, 1976, A1.
357. GAO, Federal Control of New Drug Testing Is Not Adequately Protecting Human Test Subjects and the Public, 36-41.
358. "FDA Proposes to Ban 4 Veterinary Drugs in Bid to Upstage Congressional Hearing," WSJ, March 15, 1976, 10;.
359. "Washington Wire," WSJ, August 13, 1976, 1;.
360. Mintz, "Drug Test Monitoring Called Lax," WP, January 23, 1976, A1;.
361. Mintz, "Broad Conflict of Interest," WP, July 1, 1976, A1, A18.
362. Jerome J. Avorn, Powerful Medicines (New York: Knopf, 2004);.
363. Philip B. Fontanarosa, Drummond Rennie, and Catherine D. De Angelis. "Postmarketing Surveillance-Lack of Vigilance, Lack of Trust," JAMA 292 (21) (Dec. 1, 2004): 2647-50;.
364. Simon Frantz, "How to Avoid Another Vioxx," NRDD 4 (1) (Dec. 12, 2004): 5-7.
365. Alastair J. J. Wood, C. M.Stein, and Raymond Woolsey, "Making Medicines Safer: The Need for an Independent Drug Safety Board," NEJM 339 (25) (1998): 1851-4.
366. Brian L. Strom, "How the U.S. Drug Safety System Should Be Changed," JAMA 295 (17) (May 3, 2006): 2072-5.
367. Robert A. Wilson, M.D., Feminine Forever (New York: Simon & Schuster, 1966);.
368. D. W. Johnson, "Memorandum of Telephone Conversation" (with Selig J. Levitan, representing Simon & Schuster), June 19, 1967;.
369. "FDA Investigating Doctor Who Wrote 'Feminine Forever,'" WP, August 15, 1966, A12.
370. Morton Mintz, "FDA Reveals 77 Deaths, 336 Illnesses in Users of the Pill," WP, April 14, 1968, A3;.
371. Drew Pearons and Jack Anderson, "The Washington Merry-Go-Round: FDA Lags on Data for 'Pill' Fatalities," WP, March 19, 1969, D15.
372. Mintz, "FDA Works Up Final Draft on What 'Pill' Users Should Know," WP, September 6, 1977, A7.
373. Royal College of General Practitioners, "Oral Contraception and Thromboembolic Disease," Journal of the College of General Practitioners 13 (1967): 267-79;.
374. W. B. Jennett and J. N. Cross, "Influence of Pregnancy and Oral Contraception on the Incidence of Strokes in Women of Childbearing Age," Lancet 1 (1967): 1019-23;.
375. W.H.W. Inman and M. P. Vessey, "Investigation of Deaths from Pulmonary, Coronary and Cerebral Thrombosis and Embolism in Women of Child-bearing Qge," BMJ 2 (1968): 193-9;.
376. M. P. Vessey and R. Doll, "Investigation of Relation between Use of Oral Contraceptives and Thromboembolic Disease: A Further Report," BMJ 2 (1969): 651-;.
377. P. E. Sartwell, et al., "Thromboembolism and Oral Contraceptives: An Epidemiologic Case-control Study." Second Report on the Oral Contraceptives 2, 21 (funding of the Sartell study), 3-5 (labeling revisions without industry input).
378. Pearson and Anderson, "FDA Lags on Data for 'Pill' Fatalities," WP, March 19, 1969, D15.
379. Mintz, "The Pill: What Are the Risks?" WP, April 17, 1972, B1.
380. Mintz, "FDA Watered Down Pill Warning: Ex-Aide Testifies in Oral Contraceptive Suit," WP, August 5, 1973, A16.
381. "FDA Rules Labels, Ads On Prescription Drugs Give Adverse Findings," WSJ, June 8, 1971, 10;.
382. "Pharmaceutical Group Criticizes FDA Ruling On Drug Labels and Ads," WSJ, June 9, 1971, 3;.
383. Jonathan Spivak, "FDA to Tell Makers of Oral Diabetes Drugs to Curb Ad, Label Claims, Include Warning," WSJ, May 10, 1972, 3;.
384. Jerry E. Bishop, "FDA Nears Ruling on Whether to Require Warning Labels for Antidiabetes Pills," WSJ, March 19, 1979, 23.
385. Harry Marks, "Anatomy of a Controversy: the University Group Diabetes Program study," Chapter 7 in The Progress of Experiment (New York: Cambridge University Press, 1997).
386. Mintz, "FDA Works Up Final Draft on What 'Pill' Users 'Should Know,'" WP, September 6, 1977, A7.
387. Marlene Cimons, "FDA's Approval Process Faces Challenge in New Senate Bill," LAT, July 22, 1987, A5.
388. Megan Barnett, "The New Pill Pushers," US News & World Report, April 26, 2004;.
389. Michael D. Lam (Associated Editor), "Is Everyone A Target?" Pharmaceutical Executive 24 (3) (March 2004): 56.
390. J. C. Elia, Jr., "Double-Blind Evaluation of a New Treatment for Meniere's Syndrome," JAMA 196 (2) (April 11, 1966): 187-9.
391. "Betahistine hydrochloride (serc) for Meniere's syndrome," MLDT 9 (8) (April 21, 1967): 29-30.
392. Mintz, "FDA Assailed on Anti-Dizziness Medicine," WP, October 1, 1972, F6.
393. Mintz, "Lobby Tries FDA Bypass," WP, August 4, 1968, E1.
394. "Serc, Vertigo Drug, Ordered Off Market," WP, January 5, 1973, E16.
395. Mintz, "Consumer's Union Sues U.S. on Drug," WP, December 17, 1972.
396. John Swann, Academic Scientists and the Pharmaceutical Industry: Cooperative Research in Twentieth-Century America (Baltimore: Johns Hopkins University Press, 1988);.
397. Geoffrey Tweedale, At the Sign of the Plough: Allen & Hanburys and the British Pharmaceutical Industry, 1715-1990 (London:John Murray, 1990);.
398. Nicolas Rasmussen, "The Drug Industry and Clinical Research in Interwar America: Three Types of Physician Collaborator," BullHistMed 79 (1) (2005): 50-80.
399. Louis Galambos, Networks of Innovation: Vaccine Development at Merck (New York: Cambridge University Press, 1997).
400. Alfonso Gambardella, Science and Innovation: The US Pharmaceutical Industry during the 1980s (Cambridge: Cambridge University Press, 1995), particularly chap. 4.
401. Neil Fligstein, The Transformation of Corporate Control (Cambridge, MA: Harvard University Press, 1990).
402. Abbott Laboratories, Annual Report 1966 (Abbott Park, IL: Abbott Laboratories), 3-4.
403. Squibb-BeechNut, Annual Report 1968 (New Brunswick, NJ: Squibb), 37.
404. Upjohn Company, Upjohn Annual Report 1968 (Kalamazoo, MI: Upjohn), 4.
405. Warner-Lambert, Annual Report 1973 (Morris Plains, NJ: Warner-Lambert), 35.
406. Chris Kraul, "Immunetech's Future Hinges on FDA Approval," San Diego Business Journal, June 13, 1982.
407. Herbert Lockwood, "Immunetech Uses Peptide to Intercede," San Diego Daily Transcript, March 6, 1984.
408. Gary S. Hahn, "Immunoglobulin-derived Drugs," Nature 324 (20 Nov. 1986): 283-4.
409. Barbara Yuncker, "United States Presses Probe of Heart Drug Sales," New York Post, August 7, 1962, 2.
410. FDCR 23 (46), (Nov. 13, 1961): 26.
411. Milstead, "The Food and Drug Administration's Program Against Quackery," delivered at the Yonkers Academy of Medicine, May 16, 1962;.
412. Roger Sherman, Market Regulation (New York: Pearson/Addison Wesley, 2008), chapter 23.
413. Thomas J. Perkins, Kleiner Perkins, Venture Capital, and the Chairmanship of Genentech, 1976-1995 (Regional Oral History Office, University of California, Berkeley, in 2001), 45.
414. Karl Beyer, Jr., "A Career or Two," Annual Review of Pharmacology and Toxicology 17 (1977): 1-10.
415. Jeremy Greene, Prescribing by Numbers: Drugs and the Definition of Disease (Baltimore: Johns Hopkins University Press, 2007), chapters 2 and 3.
416. Robert A. Swanson, Co-founder, CEO, and Chairman of Genentech, Inc., 1976-1996, Oral History by Sally Smith Hughes (Regional Oral History Office, The Bancroft Library, University of California, Berkeley, 2001), 80.
417. Daniel Rodgers, Atlantic Crossings (Cambridge, MA: Harvard University Press, 1998);.
418. Matthew Connelly, "Seeing Beyond the State: The Population Control Movement and the Problem of Sovereignty," Past & Present 193 (Dec. 2006): 197-233;.
419. "AHR Conversation: On Transnational History," American Historical Review 111 (5) (Dec. 2006): 1441-64.
420. Sophie Chauveau and Viviane Quirke, "The American 'Model' and the British and French Pharmaceutical Industries in the Twentieth Century," presented at the Helsinki Congress of the International Economic History Association, August 2006.
421. John W. Meyer and Brian Rowan, "Institutionalized Organizations: Formal Structure as Myth and Ceremony," American Journal of Sociology 83 (2): 340-63.
422. Walter W. Powell and Paul J. DiMaggio, eds., The New Institutionalism in Organizational Analysis (Chicago: University of Chicago Press, 1991).
423. Elisabeth Clemens, The People's Lobby: Organizational Innovation and the Rise of Interest Group Politics in the United States, 1890-1925.
424. (Wilhelm Bartmann, Zwischen Tradition und Fortschrift: aus der Geschichte der Pharmabereiche von Bayer, Hoechst und Schering von 1935-1975 (Stuttgart: Franz Steiner Verlag, 2003), III.2, 222-4.
425. Stapel, Die Arzneimittelgesetze 1961 und 1976;.
426. Beate Kirk, Der Contergan-Fall: eine unvermeidbare Arzneimittelkatastrophe? (Stuttgart: Deutsche Apotheker Verlag, 1999).
427. Abraham and Lewis, Regulating Medicines in Europe, 54 (citing an unpublished paper by Leigh Hancher and co-author).
428. Abraham and Lewis, Regulating Medicines in Europe, 53-4.
429. Charles Medawar, Power and Dependence: Social Audit on the Safety of Medicines (London: Social Audit, 1992), 74-5;.
430. Ceccoli, "Divergent Paths," 144-7.
431. P. A. Andrews, G. M. Thompson, and C. Ward, "A Regulatory View of the Medicines Act in the United Kingdom," Journal of Clinical Pharmacology 24 (1984): 6-18.
432. E. M. Tansey and L. A Reynolds, "The Committee on the Safety of Drugs," Wellcome Witnesses to Twentieth-Century Medicine [serial] (1) (April 1997), 103-35.
433. A. Herxheimer and J. Collier, "Promotion by the British Pharmaceutical Industry, 1983-8:A Critical Analysis of Sself-Regulation," BMJ 300 (Feb. 3, 1990): 307-11;.
434. Medawar, Power and Dependence, 77.
435. C. N. Roberts, "Objectives and Achievements of Pharmaceutical Regulations in Japan," in Stuart R. Walker and John P. Griffin, International Medicines Regulation: A Look Forward to 1992 (Dordrecht: Kluwer Academic, 1989);.
436. Ames Gross, "Regulatory Changes in Japan's Pharmaceutical Industry," Pacific Bridge Medical-Japan Medical Publications (Bethesda, MD: Pacific Bridge Medical, November 1998).
437. Kouseishou, A Guideline for the Statistical Analysis of Clinical Trials (Tokyo: Japanese Ministry of Public Health, 1992) (in Japanese).
438. Chihiro Hirotsu, "Impact of the ICH E9 Guideline Statistical Principles for Clinical Trials on the Conduct of Clinical Trials in Japan," DIJ (2003).
439. "FDA-style Agency for Japan," Nature Biotechnology 17 (Jan. 1999): 7.
440. Otto A. Kreuzer, "International Drug Registration," FDCLJ 43 (1988): 559;.
441. Abraham and Lewis, Regulating Medicines in Europe, 144.
442. Stuart Nightengale, "Drug Regulation and Policy Formulation," Milbank Memorial Fund Quarterly: Health and Society 59 (3): 412-44.
443. NAS, Assessing Medical Technologies, 237.
444. Rongling Deng and Kenneth I. Kaitin, "The Regulation and Approval of New Drugs in China," DIJ 37 (2004): 29-39;.
445. Young-Ok Kim, et al., "Safety Evaluation for New Drug Approval in Korea," DIJ 35 (1) (January-March 2001): 285-91.
446. Howard Lee, "Good Review Practices:The First Step Forward for the Korea Food and Drug Administration," DIJ 39 (2005): 185-92.
447. Gerald B. N. Wong and John C. W. Lin, "Drug Regulation by Singapore's Health Sciences Authority: The Role of the Centre for Drug Evaluation," DIJ 37 (2003): 15S-25S.
448. Kathleen Thelen, "Historical Institutionalism in Comparative Politics," Annual Review of Political Science (1999) 369-404.
449. Pierson, Politics in Time: History, Institutions, and Social Analysis (Princeton: Princeton University Press, 2004).
450. Eric Schickler, Disjointed Pluralism: Institutional Innovation and the Development of the U.S. Congress (Princeton: Princeton University Press, 2001).
451. Douglass North, Institutions, Institutional Change and Economic Performance (New York: Cambridge University Press, 1990), chap. 10.
452. Peter Hall and Rosemary Taylor, "Political Science and the Three New Institutionalisms," Political Studies 44 (1996): 936-57.
453. Willman, "How a New Policy Led to Seven Deadly Drugs," LAT, December 20, 2000;.
454. Horton, "Lotronex and the FDA: A Fatal Erosion of Integrity," Lancet 357 (9268) (May 19, 2001): 1544-5.
455. Marc Kaufman, "FDA Commissioner Steps Down After Rocky Two-Month Tenure," WP, September 24, 2005, A7.
456. Diedtra Henderson, "FDA Chief Quits: Tenure Marked by Turmoil," BG, September 24, 2005.
457. Patricia Guthrie, "U.S. Senate Passes FDA Revitalization Act," Canadian Medical Association Journal 177 (1) (July 3, 2007): 23.
458. Alexandra Marks, "How Drug Approval Woes Crept Up on FDA," Christian Science Monitor, November 26, 2004.
459. "Citizen Petition and Request for Administrative Stay of FDA Approval of Mifeprex for Medical Abortion," August 20, 2002.
460. Andy Coghlan, "U.S. Accelerates HIV Drug Approval," New Scientist, May 17, 2004;.
461. Jim Lobe, "Bush's AIDS Relief Plan Will Delay Drugs, Reward Big Pharma," Foreign Policy in Focus, May 26, 2004;.
462. Stephen Walker, "S.O.S. to the FDA," WSJ, August 23, 2003.
463. Meredith Wadman, "Troubling Reports Tarnish Credibility of US Drug Agency," Nature Medicine 12 (11) (Nov. 2006): 1223.
464. Philip B. Fontanarosa, Drummond Rennie, and Catherine D. De Angelis. "Postmarketing Surveillance-Lack of Vigilance, Lack of Trust," JAMA 292(21) (Dec. 1, 2004): 2647-50;.
465. R.Horton, "Lotronex and the FDA: A Fatal Erosion of Integrity," Lancet (2001) 357: 1544-5.
466. Robert Pear and Gardiner Harris, "Passage of Drug Safety Bill Was Common Goal for Two Very Different Senators," NYT, May 11, 2007.
467. Barbara Sinclair, Party Wars: Polarization and the Politics of National Policy Making (Norman: University of Oklahoma Press, 2006);.
468. Nolan McCarty, Keith T. Poole, and Howard Rosenthal, Polarized America: The Dance of Ideology and Unequal Riches (Cambridge, MA: MIT Press, 2006).
469. David E. Lewis, The Politics of Presidential Appointments: Political Control and Bureaucratic Performance (Princeton: Princeton University Press, 2008).
470. Alicia Mundy, "Wall Street Biotech Insider Gets No. 2 Job at the FDA," Seattle Times, August 24, 2005;.
471. Marc Kaufman, "FDA Official Quits Over Delay on Plan B," WP, September 1, 2005, A8.
472. Frank Davidoff and James Trussell, "Plan B and the Politics of Doubt," JAMA 296 (14) (October 11, 2006): 1775-8.
473. Adam Feuerstein, "AstraZeneca Scores Comeback Victory on Iressa," www.thestreet .com/_yahoo/tech/adamfeuerstein/10044113.html (accessed November 12, 2003).
474. Allan M. Brandt, The Cigarette Century: The Rise, Fall and Deadly Persistence of the Product that Defined America (New York: Basic Books, 2007), 361, 363.